. 2015 Mar 4;14:15. doi: 10.1186/s12944-015-0013-6

Table 9.

Effect of FVBM, F18 bioactive compound and atorvastatin on in vivo modulation of hepatic HMG-CoA reductase activity in Triton WR-1339 induced hyperlipidemic rats after 18 hours of the treatment

Group	HMG-CoA reductase activity ^†
NC	4.35 ± 0.22^*
HLC	1.21 ± 0.041^*
HLC	(+3.59 f)^a
FVT-1	2.499 ± 0.057^*
FVT-1	(−2.06 f)^a
FVT-2	4.24 ± 0.15^*
FVT-2	(−3.50 f)^a
CT	3.85 ± 0.13*
	(−3.18 f)^a
AT	2.64 ± 0.075^*
AT	(−2.18 f)^a

^†Expressed as ratio of HMG-CoA to Mevelonate; lower the ratio higher the enzyme activity.

^*Values are mean ± SD from liver homogenate of 5 rats in each group.

NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/rat; FVT-2, fed 100 mg FVBM extract/rat; CT, fed 1 mg F18 bioactive compound/rat and AT, given 1 mg atorvastatin/rat for once.

Significantly different from NC at ^ap < 0.001.

Significantly different from HLC at ^ap < 0.001.